ROIVW
Price:
$2.75
Market Cap:
$8.53B
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.[Read more]
Industry
Biotechnology
IPO Date
2021-09-27
Stock Exchange
NASDAQ
Ticker
ROIVW
According to Roivant Sciences Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -0.67. This represents a change of -2707.55% compared to the average of 0.03 of the last 4 quarters.
The mean historical PE Ratio of Roivant Sciences Ltd. over the last ten years is -1.45. The current -0.67 PE Ratio has changed 4.53% with respect to the historical average. Over the past ten years (40 quarters), ROIVW's PE Ratio was at its highest in in the June 2024 quarter at 20.91. The PE Ratio was at its lowest in in the June 2020 quarter at -549.01.
Average
-1.45
Median
-2.28
Minimum
-4.28
Maximum
1.88
Discovering the peaks and valleys of Roivant Sciences Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 48.00%
Maximum Annual PE Ratio = 1.88
Minimum Annual Increase = -229.67%
Minimum Annual PE Ratio = -4.28
Year | PE Ratio | Change |
---|---|---|
2024 | 1.88 | -143.92% |
2023 | -4.28 | 19.45% |
2022 | -3.58 | 48.00% |
2021 | -2.42 | -229.67% |
2020 | 1.87 | -186.79% |
The current PE Ratio of Roivant Sciences Ltd. (ROIVW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.99
5-year avg
-1.31
10-year avg
-1.45
Roivant Sciences Ltd.’s PE Ratio is less than Roivant Sciences Ltd. (1.79), greater than Jasper Therapeutics, Inc. (-5.29), greater than Humacyte, Inc. (-4.33), less than eFFECTOR Therapeutics, Inc. (-0.00), greater than Reviva Pharmaceuticals Holdings, Inc. (-1.05),
Company | PE Ratio | Market cap |
---|---|---|
1.79 | $8.53B | |
-5.29 | $321.43M | |
-4.33 | $674.88M | |
-0.00 | $2.82K | |
-1.05 | $36.43M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Roivant Sciences Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Roivant Sciences Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Roivant Sciences Ltd.'s PE Ratio?
How is the PE Ratio calculated for Roivant Sciences Ltd. (ROIVW)?
What is the highest PE Ratio for Roivant Sciences Ltd. (ROIVW)?
What is the 3-year average PE Ratio for Roivant Sciences Ltd. (ROIVW)?
What is the 5-year average PE Ratio for Roivant Sciences Ltd. (ROIVW)?
How does the current PE Ratio for Roivant Sciences Ltd. (ROIVW) compare to its historical average?